Cargando…

Vocal fold restoration after scarring: biocompatibility and efficacy of an MSC-based bioequivalent

BACKGROUND: There is growing interest to application of regenerative medicine approaches in otorhinolaryngological practice, especially in the framework of the therapy of vocal fold (VF) scar lesions. The used conservative and surgical methods, despite the achieved positive outcomes, are frequently...

Descripción completa

Detalles Bibliográficos
Autores principales: Svistushkin, Mikhail, Shpichka, Anastasia, Bikmulina, Polina, Fayzullin, Alexey, Zolotova, Anna, Kosheleva, Nastasia, Selezneva, Liliya, Shavkuta, Boris, Lobacheva, Viktoria, Nikiforova, Anna, Kochetkov, Peter, Kotova, Svetlana, Starostina, Svetlana, Shekhter, Anatoly, Svistunov, Andrey, Svistushkin, Valeriy, Timashev, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590531/
https://www.ncbi.nlm.nih.gov/pubmed/37865795
http://dx.doi.org/10.1186/s13287-023-03534-x
_version_ 1785124007852376064
author Svistushkin, Mikhail
Shpichka, Anastasia
Bikmulina, Polina
Fayzullin, Alexey
Zolotova, Anna
Kosheleva, Nastasia
Selezneva, Liliya
Shavkuta, Boris
Lobacheva, Viktoria
Nikiforova, Anna
Kochetkov, Peter
Kotova, Svetlana
Starostina, Svetlana
Shekhter, Anatoly
Svistunov, Andrey
Svistushkin, Valeriy
Timashev, Peter
author_facet Svistushkin, Mikhail
Shpichka, Anastasia
Bikmulina, Polina
Fayzullin, Alexey
Zolotova, Anna
Kosheleva, Nastasia
Selezneva, Liliya
Shavkuta, Boris
Lobacheva, Viktoria
Nikiforova, Anna
Kochetkov, Peter
Kotova, Svetlana
Starostina, Svetlana
Shekhter, Anatoly
Svistunov, Andrey
Svistushkin, Valeriy
Timashev, Peter
author_sort Svistushkin, Mikhail
collection PubMed
description BACKGROUND: There is growing interest to application of regenerative medicine approaches in otorhinolaryngological practice, especially in the framework of the therapy of vocal fold (VF) scar lesions. The used conservative and surgical methods, despite the achieved positive outcomes, are frequently unpredictable and do not result in the restoration of the VF’s lamina propria’s structure, which provides the mechanical properties necessary for vibration. In this connection, the aim of this study was to ascertain the safety and efficacy of a bioequivalent in the treatment of VF scars using a rabbit model of chronic damage. METHODS: The bioequivalent consisted of a hydrogel system based on a PEG-fibrin conjugate and human bone marrow-derived MSC. It was characterized and implanted heterotopically into rats and orthotopically into rabbits after VF scar excision. RESULTS: We showed that the fabricated bioequivalent consisted of viable cells retaining their metabolic and proliferative activity. While being implanted heterotopically, it had induced the low inflammatory reaction in 7 days and was well tolerated. The orthotopic implantation showed that the gel application was characterized by a lower hemorrhage intensity (p = 0.03945). The intensity of stridor and respiratory rate between the groups in total and between separate groups had no statistically significant difference (p = 0.96 and p = 1; p = 0.9593 and p = 0.97…1, respectively). In 3 days post-implantation, MSC were detected only in the tissues closely surrounding the VF defect. The bioequivalent injection caused that the scar collagen fibers were packed looser and more frequently mutually parallel that is inherent in the native tissue (p = 0.018). In all experimental groups, the fibrous tissue’s ingrowth in the adjacent exterior muscle tissue was observed; however, in Group 4 (PEG-Fibrin + MSC), it was much less pronounced than it was in Group 1 (normal saline) (p = 0.008). The difference between the thicknesses of the lamina propria in the control group and in Group 4 was not revealed to be statistically significant (p = 0.995). The Young’s modulus of the VF after the bioequivalent implantation (1.15 ± 0.25 kPa) did not statistically significantly differ from the intact VF modulus (1.17 ± 0.45 kPa); therefore, the tissue properties in this group more closely resembled the intact VF. CONCLUSIONS: The developed bioequivalent showed to be biocompatible and highly efficient in the restoration of VF’s tissue. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-023-03534-x.
format Online
Article
Text
id pubmed-10590531
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105905312023-10-23 Vocal fold restoration after scarring: biocompatibility and efficacy of an MSC-based bioequivalent Svistushkin, Mikhail Shpichka, Anastasia Bikmulina, Polina Fayzullin, Alexey Zolotova, Anna Kosheleva, Nastasia Selezneva, Liliya Shavkuta, Boris Lobacheva, Viktoria Nikiforova, Anna Kochetkov, Peter Kotova, Svetlana Starostina, Svetlana Shekhter, Anatoly Svistunov, Andrey Svistushkin, Valeriy Timashev, Peter Stem Cell Res Ther Research BACKGROUND: There is growing interest to application of regenerative medicine approaches in otorhinolaryngological practice, especially in the framework of the therapy of vocal fold (VF) scar lesions. The used conservative and surgical methods, despite the achieved positive outcomes, are frequently unpredictable and do not result in the restoration of the VF’s lamina propria’s structure, which provides the mechanical properties necessary for vibration. In this connection, the aim of this study was to ascertain the safety and efficacy of a bioequivalent in the treatment of VF scars using a rabbit model of chronic damage. METHODS: The bioequivalent consisted of a hydrogel system based on a PEG-fibrin conjugate and human bone marrow-derived MSC. It was characterized and implanted heterotopically into rats and orthotopically into rabbits after VF scar excision. RESULTS: We showed that the fabricated bioequivalent consisted of viable cells retaining their metabolic and proliferative activity. While being implanted heterotopically, it had induced the low inflammatory reaction in 7 days and was well tolerated. The orthotopic implantation showed that the gel application was characterized by a lower hemorrhage intensity (p = 0.03945). The intensity of stridor and respiratory rate between the groups in total and between separate groups had no statistically significant difference (p = 0.96 and p = 1; p = 0.9593 and p = 0.97…1, respectively). In 3 days post-implantation, MSC were detected only in the tissues closely surrounding the VF defect. The bioequivalent injection caused that the scar collagen fibers were packed looser and more frequently mutually parallel that is inherent in the native tissue (p = 0.018). In all experimental groups, the fibrous tissue’s ingrowth in the adjacent exterior muscle tissue was observed; however, in Group 4 (PEG-Fibrin + MSC), it was much less pronounced than it was in Group 1 (normal saline) (p = 0.008). The difference between the thicknesses of the lamina propria in the control group and in Group 4 was not revealed to be statistically significant (p = 0.995). The Young’s modulus of the VF after the bioequivalent implantation (1.15 ± 0.25 kPa) did not statistically significantly differ from the intact VF modulus (1.17 ± 0.45 kPa); therefore, the tissue properties in this group more closely resembled the intact VF. CONCLUSIONS: The developed bioequivalent showed to be biocompatible and highly efficient in the restoration of VF’s tissue. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-023-03534-x. BioMed Central 2023-10-21 /pmc/articles/PMC10590531/ /pubmed/37865795 http://dx.doi.org/10.1186/s13287-023-03534-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Svistushkin, Mikhail
Shpichka, Anastasia
Bikmulina, Polina
Fayzullin, Alexey
Zolotova, Anna
Kosheleva, Nastasia
Selezneva, Liliya
Shavkuta, Boris
Lobacheva, Viktoria
Nikiforova, Anna
Kochetkov, Peter
Kotova, Svetlana
Starostina, Svetlana
Shekhter, Anatoly
Svistunov, Andrey
Svistushkin, Valeriy
Timashev, Peter
Vocal fold restoration after scarring: biocompatibility and efficacy of an MSC-based bioequivalent
title Vocal fold restoration after scarring: biocompatibility and efficacy of an MSC-based bioequivalent
title_full Vocal fold restoration after scarring: biocompatibility and efficacy of an MSC-based bioequivalent
title_fullStr Vocal fold restoration after scarring: biocompatibility and efficacy of an MSC-based bioequivalent
title_full_unstemmed Vocal fold restoration after scarring: biocompatibility and efficacy of an MSC-based bioequivalent
title_short Vocal fold restoration after scarring: biocompatibility and efficacy of an MSC-based bioequivalent
title_sort vocal fold restoration after scarring: biocompatibility and efficacy of an msc-based bioequivalent
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590531/
https://www.ncbi.nlm.nih.gov/pubmed/37865795
http://dx.doi.org/10.1186/s13287-023-03534-x
work_keys_str_mv AT svistushkinmikhail vocalfoldrestorationafterscarringbiocompatibilityandefficacyofanmscbasedbioequivalent
AT shpichkaanastasia vocalfoldrestorationafterscarringbiocompatibilityandefficacyofanmscbasedbioequivalent
AT bikmulinapolina vocalfoldrestorationafterscarringbiocompatibilityandefficacyofanmscbasedbioequivalent
AT fayzullinalexey vocalfoldrestorationafterscarringbiocompatibilityandefficacyofanmscbasedbioequivalent
AT zolotovaanna vocalfoldrestorationafterscarringbiocompatibilityandefficacyofanmscbasedbioequivalent
AT koshelevanastasia vocalfoldrestorationafterscarringbiocompatibilityandefficacyofanmscbasedbioequivalent
AT seleznevaliliya vocalfoldrestorationafterscarringbiocompatibilityandefficacyofanmscbasedbioequivalent
AT shavkutaboris vocalfoldrestorationafterscarringbiocompatibilityandefficacyofanmscbasedbioequivalent
AT lobachevaviktoria vocalfoldrestorationafterscarringbiocompatibilityandefficacyofanmscbasedbioequivalent
AT nikiforovaanna vocalfoldrestorationafterscarringbiocompatibilityandefficacyofanmscbasedbioequivalent
AT kochetkovpeter vocalfoldrestorationafterscarringbiocompatibilityandefficacyofanmscbasedbioequivalent
AT kotovasvetlana vocalfoldrestorationafterscarringbiocompatibilityandefficacyofanmscbasedbioequivalent
AT starostinasvetlana vocalfoldrestorationafterscarringbiocompatibilityandefficacyofanmscbasedbioequivalent
AT shekhteranatoly vocalfoldrestorationafterscarringbiocompatibilityandefficacyofanmscbasedbioequivalent
AT svistunovandrey vocalfoldrestorationafterscarringbiocompatibilityandefficacyofanmscbasedbioequivalent
AT svistushkinvaleriy vocalfoldrestorationafterscarringbiocompatibilityandefficacyofanmscbasedbioequivalent
AT timashevpeter vocalfoldrestorationafterscarringbiocompatibilityandefficacyofanmscbasedbioequivalent